Somatropin

Overview

Somatropin is the international nonproprietary name for recombinant human growth hormone (rHGH) with the same 191-amino-acid sequence as native pituitary-derived human growth hormone (hGH). It is produced by recombinant DNA technology in bacterial (E. coli) or mammalian expression systems and has been in clinical use since the mid-1980s, replacing cadaveric pituitary-derived hGH after the latter was implicated in Creutzfeldt-Jakob disease transmission.

Growth hormone sits at the apex of the somatotropic axis. It is secreted in pulsatile fashion by anterior pituitary somatotrophs in response to hypothalamic GHRH and inhibited by somatostatin. Its systemic effects include stimulation of hepatic insulin-like growth factor 1 (IGF-1) production, lipolysis in adipose tissue, linear bone growth in pediatric populations, and modulation of carbohydrate and protein metabolism.

Somatropin is approved for multiple pediatric and adult indications including growth hormone deficiency, Turner syndrome, chronic renal insufficiency in children, AIDS-associated wasting, and short bowel syndrome. It is also on the WADA prohibited list and is a heavily regulated prescription medicine.

Structure / Chemistry

• Length: 191 amino acids
• Molecular weight: approximately 22.1 kDa
• Disulfide bonds: Two intramolecular disulfides (Cys53–Cys165 and Cys182–Cys189)
• Glycosylation: None in the canonical 22 kDa form (minor circulating 20 kDa splice variant exists)
• Three-dimensional fold: Four-helix bundle characteristic of the cytokine superfamily

Recombinant somatropin preserves the full native sequence, distinguishing it from older pituitary extract preparations and from methionyl-hGH (somatrem), which carried an extra N-terminal methionine. Long-acting somatropin analogs with fatty-acid acylation or PEGylation (e.g., somapacitan, lonapegsomatropin) have more recently extended dosing intervals to weekly.

Mechanism of Action

Somatropin binds the growth hormone receptor (GHR), a homodimeric type I cytokine receptor expressed broadly but most relevantly on hepatocytes, chondrocytes, and adipocytes:

• Receptor dimerization and conformational rearrangement upon GH binding
• JAK2 transactivation and STAT5 recruitment, the dominant signaling pathway
• Hepatic IGF-1 induction, producing the systemic anabolic effects attributed to GH signaling
• Direct lipolytic effect on adipose tissue via intracellular signaling to hormone-sensitive lipase
• Insulin-antagonist effect on glucose homeostasis at high chronic exposure

Much of somatropin's clinical effect is mediated by IGF-1, though direct GHR signaling at target tissues also contributes, particularly in adipose tissue and skeletal muscle.

Research Summary

Pharmacokinetics

Subcutaneous somatropin produces plasma peak concentrations 2–6 hours post-injection with an apparent half-life of 2–4 hours. Bioavailability is approximately 70–90% via SC route. Intravenous administration yields a shorter half-life (~20 minutes) reflecting rapid systemic clearance.

Hepatic and renal metabolism predominate, with cleavage by endopeptidases in target tissues and subsequent renal filtration of fragments. IGF-1 induction in plasma peaks 16–28 hours after injection and integrates the pharmacodynamic signal of pulsatile GH exposure. Long-acting analogs extend effective dosing intervals by slowing absorption and clearance.

Common Discussion Topics

• Pediatric GHD, Turner syndrome, and other FDA-approved pediatric indications
• Adult GHD and body composition endpoints
• Off-label anti-aging use and regulatory concerns
• WADA prohibited status and current detection methods
• Long-acting analogs (somapacitan, lonapegsomatropin, TransCon hGH)

Related Compounds

• IGF-1 LR3 — downstream effector analog
• CJC-1295 — GHRH analog upstream of GH release
• Ipamorelin — GH secretagogue on ghrelin pathway
• Hexarelin — GH-releasing peptide
• Macimorelin — oral ghrelin receptor agonist used for GHD diagnosis

Educational information only. Somatropin is a prescription medicine, regulated across jurisdictions, and prohibited in sport. This article does not constitute medical, performance, or dosing advice.